Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 million ...
Third-quarter 2024 earnings down year-over-year on lower commodity prices, refining margins. A group of 53 US-based oil and gas producers and refiners announced combined net earnings of $24.9 billion ...
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results